2416941-68-7
Chemical Structure
HMG499
- CAS No.: 2416941-68-7
- Formula:C33H54O3
- Molecular Weight:498.78
IUPAC Name: (3S,7R,8S,9S,10R,13R,14S,17R)-17-((R)-6-allyl-6-hydroxynon-8-en-2-yl)-4,4,10,13-tetramethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
InChIKey: LPLLZSOEZAVGBO-XHBYIXHHSA-N
SMILES: C[C@H](CCCC(CC=C)(CC=C)O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C=C4C(C)(C)[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
Biological Activity: HMG499 is an orally active HMGCR degrader with an EC50 of 0.39 μM. HMG499 induces HMG-CoA reductase degradation through Insig-dependent ubiquitination and proteasomal degradation pathways. HMG499, alone or in combination with Lovastatin (HY-N0504), reduces in vivo cholesterol and triglyceride levels and alleviates atherosclerotic plaques. HMG499 can be used in research related to hypercholesterolemia, hyperlipidemia, and atherosclerosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HMG499 | 96.12% | HMG499 is an orally active HMGCR degrader with an EC50 of 0.39 μM. HMG499 induces HMG-CoA reductase degradation through Insig-dependent ubiquitination and proteasomal degradation pathways. HMG499, alone or in combination with Lovastatin (HY-N0504), reduces in vivo cholesterol and triglyceride levels and alleviates atherosclerotic plaques. HMG499 can be used in research related to hypercholesterolemia, hyperlipidemia, and atherosclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jiang SY, et al. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nature communications. 2018 Dec 03;9(1):5138. [Content Brief]
- [2]. Zhou Y, et al. HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin. Biochemical and biophysical research communications. 2023 Oct 15;677:13-19. [Content Brief]
